Indian Generic Drug Maker Strides Acrolab Receives Tentative FDA Approval For Combination Antiretroviral

Main Category: HIV / AIDS
Also Included In: Regulatory Affairs / Drug Approvals;  Pharma Industry / Biotech Industry
Article Date: 27 Mar 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions

FDA on Tuesday announced that it has given tentative approval to Indian generic pharmaceutical company Strides Acrolab for its fixed-dose antiretroviral drug that contains lamivudine, nevirapine and stavudine, Reuters/Yahoo! Malaysia News reports (Reuters/Yahoo! Malaysia News, 3/26). Tentative FDA approval means that although existing patents or other issues prevent marketing of the drug in the U.S., the drug is qualified for consideration in the President's Emergency Plan for AIDS Relief (FDA release, 3/24). The FDA approval is for multiple strengths of the combination therapy, according to Dow Jones (Dow Jones, 3/24). The two versions are 30 milligrams, 150 mg and 200 mg of stavudine, lamivudine and nevirapine, respectively, and 40 mg, 150 mg and 200 mg of stavudine, lamivudine and nevirapine, respectively (FDA release, 3/24).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.